SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Snap, Inc. operates as a technology company, which engages in the provision of a visual messaging application that was created to help people communicate through short videos and images. The company was founded by Frank Reginald Brown IV, Evan Thomas Spiegel, and Robert C. Murphy in 2010 and is headquartered in Santa Monica, CA.

Snap Inc - Ordinary Shares - Class A

Snap Inc

Snap's stock is surging as investors react to a Q3 earnings beat, a $500 million stock buyback, and a new $400 million AI partnership with Perplexity. The community is buzzing about the potential for a short squeeze and upgraded price targets, while also weighing concerns about profitability and the long-term sustainability of the rally.

Celsius Holdings, Inc. engages in the development, marketing, sale, and distribution of functional drinks and liquid supplements. It also offers post-workout functional energy drinks and protein bars. The company was founded in April 2004 and is headquartered in Boca Raton, FL.

Celsius Holdings Inc

CELH is trending as investors anticipate upcoming earnings results, with many in the community expecting strong numbers driven by growth and the Alani Nu acquisition. Despite overall market uncertainty, the community expresses long-term confidence in CELH's execution and potential, while also closely monitoring potential short-term volatility and market manipulation.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricor Therapeutics is trending as investors anticipate Phase 3 data for their DMD treatment, deramiocel, expected mid-Q4, with the community actively discussing potential FDA approval pathways. Discussions also involve the StealthX exosome platform and recent job postings at Capricor and NS Pharma, hinting at possible positive outcomes. Community members are closely monitoring short interest and options activity, speculating on potential market reactions following the data release.

Avantis is the largest RWA perps DEX in DeFi, built on and backed by Base. Avantis allows users to trade crypto and real-world assets (RWAs), including FX, commodities, indices, and equities. Backed by Pantera and Coinbase, Avantis is the largest DEX on Base by volumes, and brings institutional-grade products to DeFi, letting users trade with up to 500x leverage in a transparent, permissionless environment.  Avantis is best known for launching zero-fee perpetuals (ZFP) — a first-of-its-kind primitive where traders only pay fees if they profit. They've also brought leveraged RWAs onchain. This has driven explosive growth: over $20B+ in cumulative volume and 15M+ run-rate revenues since Febrruary 2024.

Avantis

Avantis ($AVNT) is trending as community members discuss its tokenomics, specifically the locked dev tokens until February and scheduled buybacks, which some believe will naturally increase the coin price.  Concerns about competitors potentially suppressing the token's price and calls for fair play are also circulating.  Traders are actively watching key price levels and anticipating potential volatility, with some suggesting it's time for a rebound.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bull 3X Shares

Direxion Daily Semiconductor Bull 3X Shares

SOXL is trending as traders assess the semiconductor sector's near-term trajectory amidst AI optimism and US-China trade concerns. Community discussions include reactions to earnings reports from key semiconductor companies and speculation about upcoming economic data releases and Federal Reserve actions. Bullish sentiment persists, while some are wary of overvaluation and the potential for a pullback.

$SWEAT is the beating heart of the Movement Economy—a groundbreaking token that transforms physical activity into real-world value. Minted through movement, $SWEAT rewards your steps with a crypto asset that you can earn, trade, or grow. The team states that their app has increased their users’ physical activity by an average of 20%, creating a healthier society and reducing burdens on global healthcare systems. With over 20 million holders, SWEAT is eliminating barriers and making Web3 accessible to everyone, one step at a time.

Sweat Economy

Sweat Economy is trending as the community discusses its potential for future growth and staking opportunities. Many users are accumulating and staking $SWEAT, motivated by the project's concept of earning crypto through walking and its potential for long-term gains. The conversation also highlights anticipation for increased utility and adoption of the Sweat Wallet in the US.

Caledonia Mining Corp. Plc engages in the exploration, development, and production of gold and other precious metals from its mineral properties. Its projects include Blanket Gold Mine and Maligreen. The company was founded on February 5, 1992 and is headquartered in St. Helier, the United Kingdom.

Caledonia Mining Corporation Plc

Caledonia Mining Corporation ($CMCL) is trending due to upcoming earnings and discussions around its potential growth, particularly the Bilboes project which could significantly increase production; the earnings are scheduled to be released Monday before the market opens. Community members are weighing the company's profitability against the political risks of operating in Zimbabwe, with some anticipating a positive impact from rising gold prices and others concerned about potential dilution from financing activities. Recent discussions also touch on the stock's valuation relative to its growth potential and comparison to other gold miners.

Dynavax Technologies Corp. is a biopharmaceutical company, which engages in the provision of discovery, development, and commercialization of novel vaccines and immuno-oncology therapeutics. Its product includes HEPLISAV-B, which prevents infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older. The company was founded by Lawrence M. Lichtenstein, Dennis A. Carson, and Eyal Raz on August 29, 1996 and is headquartered in Emeryville, CA.

Dynavax Technologies Corp.

DVAX is trending due to a new $100 million share buyback program and updates regarding a partnership with VXRT for a novel oral COVID-19 vaccine. The community is discussing the potential financial benefits and strategic implications of this agreement, as well as concerns about delays in the FDA study protocol for HLAD in adults on hemodialysis. Investors are also weighing in on the impact of Deep Track's involvement and management's capital allocation decisions.

Chime Financial, Inc. engages in the design and development of a digital banking application. Its mobile app, Chime, provides online banking, fee-free overdraft, mobile banking, automatic savings, mobile payments, and security and control capabilities. The company was founded by Christopher R. Britt and Ryan King in 2012 and is headquartered in San Francisco, CA.

Chime Financial Inc - Ordinary Shares - Class A

Chime Financial, Inc.

Chime Financial's stock is trending amid discussions about its recent earnings report, which appears to have surpassed expectations, including a share repurchase program. The community is debating the sustainability of some revenue streams and expressing varied opinions on the company's valuation relative to its peers. Some investors believe the stock is undervalued and poised for growth, while others cite concerns about a potential lockup expiration and competition.

Kura Oncology, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the research and development of medicines for the treatment of cancer. Its pipeline includes Tipifarnib, which is a Farnesyl transferase inhibitor for HRAS Mutant Solid Tumors, Chronic Myelomonocytic Leukemia, KO-947, which is an ERK inhibitor for MAPK Pathway Tumors, and KO-539, which is a Menin MLL inhibitor for acute leukemias. The company was founded by Troy E. Wilson, Yi Liu, Pingda Ren and Antonio Gualberto on August 22, 2014 and is headquartered in San Diego, CA.

Kura Oncology Inc

Kura Oncology is trending amid discussions about its drug ziftomenib and its potential competition with Syndax's Revuforj, particularly regarding safety profiles and efficacy in treating AML. Community members are debating the clinical and legal implications of Revuforj's black box warning for cardiac risk compared to ziftomenib, with some suggesting Kura's drug may become the preferred choice for doctors due to its potentially cleaner safety profile. Investors are also closely watching for the PDUFA approval decision expected by the end of November.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Is Schwab Fundamental International Small Company Index ETF (FNDC) a Strong ETF Right Now?

Shares of cannabis retailer Curaleaf Holdings dropped nearly 10% on Monday after the company posted mixed fourth-quarter earnings.&nbsp;While Curaleaf reported a profit of $12.4 million, or $0.02 per share, compared with a $5 million loss from the same period last year, revenue declined to $331.1 million from $345.3 million.Chairman and CEO Boris Jordan highlighted the company's profitability metrics, noting that Curaleaf achieved an adjusted gross margin of 48% and an adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) of $76 million.&nbsp;He also pointed to the company's strengthened cash position, with $107 million in cash at year-end, and operating and free cash flow of $163 million and $70 million, respectively."Over the past two quarters, my primary objective has been to amplify our strengths, address key challenges, and stabilize the business," Jordan said."Having successfully achieved this, we are now forging ahead with our 'Return to our ROOTS' initiative—an ambitious strategy centered on driving organic growth, optimizing margins and cash flow, and reducing debt."Message volume for Curaleaf surged 366% on Stocktwits following the earnings release, with posts reflecting a divide between bullish and bearish sentiment.&nbsp;One trader emphasized Curaleaf's dominant position in the industry, its $1.34 billion annual sales, and improving cash flow, arguing that the company remains well-positioned despite foreign exchange headwinds affecting international sales.&nbsp;<stembedurl>https://stocktwits.com/angelfromsky/message/606622013</stembedurl>Others, however, focused on the revenue decline, with one trader calling it a "solid miss as usual" and another predicting that the stock would slip below $1.<stembedurl>https://stocktwits.com/symbol/CURLF/earnings</stembedurl>Curaleaf and its industry peers have been&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.marketwatch.com/story/trulieve-curaleaf-and-green-thumb-launch-hemp-based-thc-drinks-as-cannabis-reforms-stall-2f03d249">expanding</a> into THC-infused beverages as federal cannabis legalization efforts stall.&nbsp;Last week, the company announced a partnership with Total Wine &amp; More to distribute its Select Zero Proof line of hemp-derived THC seltzers.Curaleaf stock has lost over 28% this year.&nbsp;According to Koyfin data, it trades about 240% below the average price target of $4.02 from 10 analysts. Seven rate it a 'buy,' one assigns a 'strong buy,' and two have a 'hold' rating.For updates and corrections, email newsroom[at]stocktwits[dot]com.

A Curaleaf medical cannabis dispensary in Forest Hills, Queens, NY. (Photo by: Lindsey Nicholson/UCG/Universal Images Group via Getty Images)

Curaleaf's Q4 Profit Swing Ignites Retail Chatter, But Shrinking Revenue Dampens The High

Chairman and CEO Boris Jordan pointed to the company's strengthened cash position, with $107 million in cash at year-end, and operating and free cash flow of $163 million and $70 million.

Equity

Chairman and CEO Boris Jordan pointed to the company's strengthened cash position, with $107 million in cash at year-end, and operating and free cash flow of $163 million and $70 million.


FNDC
Schwab Strategic Trust - Schwab Fundamental International Small Company Index ETF

Feed

News

Sentiment

Fundamentals

Info

Latest FNDC News

FNDCSchwab Strategic Trust - Schwab Fundamental International Small Company Index ETF